Single-dose pharmacokinetics and tolerability of pegylated interferon-α2b in young and elderly healthy subjects

British Journal of Clinical Pharmacology

Volumn 56, Issue 1, 2003, Pages 131-134

  Gupta, Samir K ^a   Glue, Paul ^a   Jacobs, Sheila ^a   Belle, Donna ^a   Affrime, Melton ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Elderly; Interferon 2b; Pegylation; Pharmacokinetics; Young

Indexed keywords

MACROGOL; PEGINTERFERON ALPHA2B; RECOMBINANT ALPHA2B INTERFERON;

ADULT; AGE DISTRIBUTION; AGED; ANALYSIS OF VARIANCE; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; DOSE CALCULATION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG FORMULATION; DRUG HALF LIFE; DRUG TOLERABILITY; FEMALE; FLU LIKE SYNDROME; HEADACHE; HEART INFARCTION; HUMAN; HUMAN CELL; HUMAN EXPERIMENT; MALE; OPEN STUDY; PRIORITY JOURNAL; SIDE EFFECT;

ADULT; AGED; AGED, 80 AND OVER; ANALYSIS OF VARIANCE; AREA UNDER CURVE; FEMALE; HUMANS; INTERFERON ALFA-2B; MALE; MIDDLE AGED;

EID: 0037998720     PISSN: 03065251     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2125.2003.01836.x     Document Type: Article

References (13)

1. Bocci V, Pacini A, Muscettola M, Pessina GP, Paulesu L, Bandinelli L. The kidney is the main site of interferon catabolism. J Interferon Res 1982; 2: 309-314.
2. Bocci V, Pacini A, Bandinelli L et al. The role of liver in the catabolism of human α- and β-interferon. J General Virol 1982; 60: 397-400.
3. Glue P, Fang J, Rouzier-Panis R et al. Pegylated interferon-α2b: pharmacokinetics, pharmacodynamics, safety, and preliminary efficacy data. Clin Pharmacol The 2000; 68: 556-567.
4. Bukowski R. Treating cancer with PEG Intron: pharmacokinetic profile and dosing guidelines for an improved interferon alfa-2b formulation. Cancer 2002; 95: 389-396.
5. Marcus EL, Tur-Kaspa R. Viral hepatitis in older adults. J Am Geriatr Soc 1997; 45: 755-763.
6. Turner N, Scarpace PJ, Lowenthal DT. Geriatric pharmacology: basic clinical considerations. Annu Rev Pharmacol Toxicol 1992; 32: 271-302.
7. Matzke GR, Millikin SP. Influence of renal function and dialysis on drug disposition. In Applied pharmacokinetics, edition 3rd edn, eds Evans WE, Schentag JJ, Jusko WJ. Vancouver, WA: Applied Therapeutics, Inc., 1992; 8.1-8.49.
8. Glue P, Rouzier-Panis R, Raffanel C et al. A dose-ranging study of pegylated interferon alfa-2b and ribavirin in chronic hepatitis C. Hepatology 2000; 32: 647-653.
9. Chatelut E, Rostaing L, Gregoire N et al. A pharmacokinetic model for alpha interferon administered subcutaneously. Br J Clin Pharmacol 1999; 47: 365-371.
10. Uchihara M, Izumi N, Sakai Y et al. Interferon therapy for chronic hepatitis C in hemodialysis patients: increased serum levels of interferon. Nephron 1998; 80: 51-56.
11. Jen JF, Glue P, Ezzet F et al. Population pharmacokinetic analysis of pegylated interferon alfa-2b and interferon alfa-2b in patients with chronic hepatitis C. Clin Pharmacol Ther 2001; 69: 407-421.
12. Bocci V. Metabolism of protein anticancer agents. Pharmacol Ther 1987; 34: 1-49.
13. Sonnenblick M, Rosin A. Cardiotoxicity of interferon. Chest 1991; 99: 557-561.